Notices. Notice; correction

252 words·~1 min read·/register/2011/09/23/2011-24400

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2010-N-0318] Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 27 New Drug Applications and 58 Abbreviated New Drug Applications; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Notice; correction. SUMMARY: The Food and Drug Administration

(FDA)is correcting a notice that appeared in the **Federal Register** of July 21, 2010 (75 FR 42455). The document withdrew approval of 27 new drug applications

(NDAs)and 58 abbreviated new drug applications (ANDAs) from multiple applicants. The published document excluded a footnote in the table. This document corrects that error. FOR FURTHER INFORMATION CONTACT: Joyce Strong, Office of Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 3208, Silver Spring, MD 20993-0002, 301-796-9148. SUPPLEMENTARY INFORMATION: In FR Doc. 2010-17785, appearing on page 42455, in the **Federal Register** of Wednesday, July 21, 2010, the following correction is made: 1. On page 42456, in Table 1, under the “Drug” column, correct the entry for “Proventil (albuterol USP) Inhalation Aerosol” to read “Proventil (albuterol USP) Inhalation Aerosol 1 ”. 2. On page 42456, at the end of the table, add footnote number 1 to read: This product included an oral pressurized metered-dose inhaler that contained chlorofluorocarbons

(CFCs)as a propellant. CFCs may no longer be used as a propellant for any albuterol metered-dose inhalers. (See 70 FR 17168, April 4, 2005.) Dated: September 19, 2011. Leslie Kux, Acting Assistant Commissioner for Policy. [FR Doc. 2011-24400 Filed 9-22-11; 8:45 am]